Tyra Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
TYRA Biosciences reports significant progress in its FGFR-targeted precision medicine pipeline, advancing three lead candidates into Phase 2 trials and detailing financial results for fiscal year 2025.
NASDAQ
Tyra Biosciences details its financial performance for 2024 and highlights key advancements in its clinical-stage precision medicine programs.
NASDAQ
Tyra Biosciences' 10-K filing highlights its clinical-stage progress in developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, with a focus on overcoming drug resistance.